—I agree with Dr Regester that analgesic nephropathy may be underrepresented in the population requiring dialysis (relating to the population with chronic renal disease) because of an increased mortality in patients who take large doses of analgesics. Neither the data of Nanra nor those outlined by Dr Regester include appropriate controls; therefore it is difficult at this time to assess the effect of increased mortality on the preponderance of analgesic nephropathy in the population requiring dialysis. This problem deserves further study.
As Dr Regester points out, analgesic nephropathy is an important public health problem. It is a problem that every physician should be aware of, since it can be prevented.